Base case: current eligibility requirements maintained through to 2035Treat 70% + cirrhosis: treat 70% of eligible patients if current guidelines extended to include all cirrhotic patientsTreat 70% + ULN: treat 70% of eligible patients if current guidelines lowered ALT restriction to ULNTreat 70% + ≥2000 IU/mL: treat 70% of eligible patients if current guidelines removed HBeAg and ALT restrictions and included all those with HBV DNA ≥2000 IU/mL. The gene discussed is GPT; the disease is Cirrhosis.